Stocks and InvestingStocks and Investing
Fri, November 11, 2022
Thu, November 10, 2022

Joel Beatty Downgraded (ARCT) to Sell and Held Target at $18 on, Nov 10th, 2022


Published on 2024-10-28 00:05:48 - WOPRAI, Joel Beatty
  Print publication without navigation


Joel Beatty of Baird, Downgraded "Arcturus Therapeutics Holdings Inc." (ARCT) to Sell and Held Target at $18 on, Nov 10th, 2022.

Joel has made no other calls on ARCT in the last 4 months.



There are 6 other peers that have a rating on ARCT. Out of the 6 peers that are also analyzing ARCT, 1 agrees with Joel's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Gena Wang of "Barclays" Upgraded from Sell to Hold and Increased Target to $25 on, Wednesday, November 2nd, 2022


These are the ratings of the 5 analyists that currently disagree with Joel


  • Yigal Nochomovitz of "Citigroup" Upgraded from Hold to Strong Buy on, Thursday, November 3rd, 2022
  • Pete Stavropoulos of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $44 on, Wednesday, November 2nd, 2022
  • John Abbott of "Wells Fargo" Maintained at Buy with Decreased Target to $98 on, Wednesday, August 10th, 2022
  • Steven Seedhouse of "Raymond James" Downgraded from Hold to Sell on, Wednesday, August 10th, 2022
  • Pete Stravropoulos of "Cantor Fitzgerald" Initiated at Buy and Held Target at $39 on, Tuesday, July 19th, 2022